A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer’s Disease in Asia
Issued Date
2024-08-27
Resource Type
ISSN
13872877
eISSN
18758908
Scopus ID
2-s2.0-85202868259
Pubmed ID
39058448
Journal Title
Journal of Alzheimer's Disease
Volume
101
Issue
1
Start Page
1
End Page
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Alzheimer's Disease Vol.101 No.1 (2024) , 1-12
Suggested Citation
Lee J.H., Jia J., Ji Y., Kandiah N., Kim S.Y., Mok V., Pai M.C., Senanarong V., Suh C.H., Chen C. A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer’s Disease in Asia. Journal of Alzheimer's Disease Vol.101 No.1 (2024) , 1-12. 12. doi:10.3233/JAD-240684 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101122
Title
A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer’s Disease in Asia
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Advances in biomarker-based diagnostic modalities, recent approval of anti-amyloid monoclonal antibodies for early Alzheimer’s disease (AD; mild cognitive impairment or mild dementia due to AD) and late-stage clinical development of other disease-modifying therapies for AD necessitate a significant paradigm shift in the early detection, diagnosis and management of AD. Anti-amyloid monoclonal antibodies target the underlying pathophysiological mechanisms of AD and have demonstrated a significant reduction in the rate of clinical decline in cognitive and functional outcome measures in patients with early AD. With growing recognition of the benefit of early interventions in AD, an increasing number of people may seek diagnosis for their subjective cognitive problems in an already busy medical system. Various factors such as limited examination time, lack of expertise for cognitive assessment and limited access to specialized tests can impact diagnostic accuracy and timely detection of AD. To overcome these challenges, a new model of care will be required. In this paper, we provide practical guidance for institutional readiness for anti-amyloid therapies for early AD in Asia, in terms of best practices for identifying eligible patients and diagnosing them appropriately, safe administration of anti-amyloid monoclonal antibodies and monitoring of treatment, managing potential adverse events such as infusion reactions and amyloid-related imaging abnormalities, and cross-disciplinary collaboration. Education and training will be the cornerstone for the establishment of new pathways of care for the identification of patients with early AD and delivery of anti-amyloid therapies in a safe and efficient manner to eligible patients.